Business Context and Reporting Period
Company: Aadi Bioscience, Inc. (Note: The input metadata referenced "Whitehawk Therapeutics," but the filing text explicitly identifies the registrant as Aadi Bioscience, Inc.)
Reporting Period: Quarterly period ended June 30, 2024 (Form 10-Q)
Business Overview: Aadi is a biopharmaceutical company focused on developing and commercializing precision therapies for cancers with alterations in the mTOR pathway. Its lead product, FYARRO (sirolimus protein-bound particles), is FDA-approved for the treatment of advanced malignant perivascular epithelioid cell tumor (PEComa). The company operates as a single segment and is classified as a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2024 |
Six Months Ended June 30, 2024 |
Six Months Ended June 30, 2023 |
|---|---|---|---|
| Revenue (Product Sales, Net) | $6,179 | $11,532 | $12,069 |
| Operating Expenses | $21,763 | $46,628 | $48,439 |
| Selling, General & Administrative | $7,892 | $18,512 | $22,983 |
| Research & Development | $13,093 | $26,686 | $24,271 |
| Cost of Goods Sold | $778 | $1,430 | $1,185 |
| Net Loss | $(14,583) | $(32,872) | $(33,194) |
| Cash, Cash Equivalents & Short-Term Investments | $78,568 (as of June 30, 2024) | ||
| Accumulated Deficit | $(301,835) (as of June 30, 2024) |
Liquidity: As of June 30, 2024, the company held $41.1 million in cash and cash equivalents and $37.4 million in short-term investments. Management believes these resources are sufficient to fund operations into the fourth quarter of 2025.
Material Changes vs. Prior Period
- Revenue: Net product sales decreased slightly to $11.5 million for the six months ended June 30, 2024, compared to $12.1 million in the prior year period. The decline is attributed to distributor ordering patterns and fewer new patient initiations.
- Operating Expenses: Total operating expenses decreased by approximately $1.8 million year-over-year for the six-month period.
- SG&A: Decreased by $4.5 million, driven by reductions in commercial/marketing expenses ($2.4 million) and legal/other expenses ($2.0 million).
- R&D: Increased by $2.4 million, primarily due to higher clinical development expenses ($2.8 million) related to the PRECISION1 trial and increased clinical drug product manufacturing costs ($1.9 million).
- Net Loss: Net loss narrowed slightly to $32.9 million for the six months ended June 30, 2024, compared to $33.2 million in the prior year period.
- Other Income: Net other income decreased to $2.2 million from $3.2 million year-over-year, primarily due to a decrease in short-term investments held.
Guidance, Outlook, Risks, and Unusual Items
- Clinical Outlook: The PRECISION1 trial (tumor-agnostic Phase 2 study for TSC1/TSC2 alterations) was fully enrolled in April 2024. Results are anticipated in early 2025. The company is also enrolling patients in Phase 2 studies for endometrioid endometrial cancer (EEC) and neuroendocrine tumors (NETs).
- Collaboration Termination: In May 2024, the company mutually agreed to terminate its collaboration with Mirati Therapeutics regarding the combination of adagrasib and FYARRO. The Phase 1/2 study has been discontinued.
- Legal Contingency: An ongoing arbitration with EOC Pharma (Hong Kong) Limited regarding the termination of a 2022 license agreement is expected to conclude in the second half of 2024. The company disputes EOC's allegations of material breach and cannot estimate potential losses.
- Upcoming Obligations: The company expects to make a $5.8 million payment to Bristol-Myers Squibb (BMS) by August 26, 2024, related to a prior license agreement amendment.
- Risks: The company faces significant risks related to its dependence on a single product (FYARRO), reliance on third-party manufacturers (Fresenius Kabi), and the need for additional capital to fund operations and clinical trials. Stock price volatility and potential dilution from future equity offerings are also noted.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $78.6 million cash position against the upcoming $5.8 million BMS payment and ongoing burn rate to confirm the ability to fund operations through late 2025.
- EOC Arbitration Outcome: Monitor the second-half 2024 arbitration decision with EOC Pharma, as an adverse ruling could result in significant, unquantified liabilities.
- PRECISION1 Trial Data: Track the interim analysis results expected in Q3 2024 and final results in early 2025, as these are critical for potential label expansion and future revenue growth.
- Manufacturing Supply Chain: Confirm the status of the Fresenius Kabi supply agreement (extended to September 30, 2024) and the company's plan for long-term manufacturing redundancy.
- Revenue Trends: Assess whether the decline in FYARRO sales is a temporary fluctuation or a structural trend affecting the commercialization strategy.